Federal: HR4388

Bill Summary

HR 4388, the PREP Repeal Act, seeks to repeal sections 319F-3 and 319F-4 of the Public Health Service Act, which currently grant pharmaceutical manufacturers broad liability immunity for products developed, administered, or distributed during declared public health emergencies. The bill would eliminate this legal shield and allow individuals to pursue civil remedies under federal or state law for injuries caused by emergency countermeasures, biologics, drugs, and devices. The legislation would also rescind unobligated balances in the Covered Countermeasure Process Fund. These provisions would apply retroactively to pending legal actions and prospectively to claims filed after enactment, with a severability clause protecting the remainder of the Public Health Service Act.

Why It Matters to MAHA

This bill directly aligns with core MAHA principles of patient autonomy, transparency, and accountability in healthcare. The PREP Act's blanket liability immunity has removed critical incentives for pharmaceutical manufacturers to prioritize safety and transparency during emergencies, undermining informed consent and the ability of injured parties to seek redress. By restoring the right to legal recourse, HR 4388 restores market accountability and forces manufacturers to maintain rigorous safety standards rather than rely on government-granted protection from liability. This legislation empowers patients and their families to hold producers accountable for harm, which strengthens the entire healthcare system's integrity and trustworthiness. Removing artificial legal barriers to justice is essential to rebuilding public confidence in pharmaceutical products and manufacturers.